Jamet: Development of multi-specific T-cell engaging antibodies to target mixed-phenotype acute leukemia phase 1 indirect costs award
Jamet: Development of multi-specific T-cell engaging antibodies to target mixed-phenotype acute leukemia phase 1 indirect costs award